Group 1: Mergers and Acquisitions Overview - During the period from September 5 to September 11, 2025, two listed companies announced new mergers and acquisitions, namely *ST Bosen and Xiangrikui, involving two merger and acquisition events in the textile and apparel, and pharmaceutical industries [1][7]. Group 2: *ST Bosen - *ST Bosen is focused on men's apparel design, production, and sales, with its main brand "Bosen Men's Wear" promoting the concept of "comfortable business men's clothing" [2][7]. - The company plans to sell 35% of its stake in Shaanxi Bosen Apparel Intelligent Manufacturing Co., Ltd. to Nantong Erfangji Co., Ltd. in cash, aiming to optimize its asset structure and improve cash flow [2][7]. - Shaanxi Bosen was established on April 13, 2021, with a registered capital of 200 million yuan, and is primarily engaged in clothing manufacturing and sales [2][7]. Group 3: Xiangrikui - Xiangrikui is engaged in the research, production, and sales of pharmaceuticals, focusing on anti-infection, cardiovascular, and digestive system drugs, with a complete integrated industrial chain [3][8]. - The company plans to acquire a controlling stake in Zhangzhou Xipu Material Technology Co., Ltd. and 40% of Zhejiang Beid Pharmaceutical Co., Ltd. through issuing shares and/or cash payments, while also raising matching funds [3][8]. - Major products include clarithromycin raw materials and tablets, widely used for treating infectious diseases, hypertension, and digestive system diseases [3][8].

Core Viewpoint - Company is planning a significant asset restructuring involving the acquisition of stakes in two companies, one in the semiconductor materials industry and the other in the pharmaceutical sector [2][3]. Group 1: Major Asset Restructuring - Company is planning to acquire a controlling stake in Zhangzhou Xipu Materials Technology Co., Ltd. and 40% of Zhejiang Beid Pharmaceutical Co., Ltd. through share issuance and/or cash payment [3]. - The transaction is still in the planning stage, and the valuations of Xipu Materials and Beid Pharmaceutical have not been finalized [3]. - The restructuring is expected to be significant but will not change the actual control of the company, thus not constituting a reverse listing [3]. Group 2: Transaction Timeline and Agreements - All parties involved have signed a letter of intent regarding the transaction [4]. - Company expects to disclose the transaction plan within 10 trading days, by September 22, 2023, or will resume trading and terminate the restructuring plans if not disclosed by that date [4]. Group 3: Acquisition Targets - Beid Pharmaceutical, a subsidiary of the company, generated revenue of 144 million yuan and a net profit of 4.04 million yuan in the first half of the year, with a net asset value of 346 million yuan as of June 30, 2025 [5]. - Xipu Materials operates in the semiconductor industry, focusing on electronic-grade materials, and is currently the largest supplier of certain electronic-grade gases [5]. Group 4: Historical Context and Market Expectations - Company has a history of restructuring to adjust its business structure, having transitioned from solar energy to pharmaceuticals to improve profitability and asset quality [6]. - Market expectations for the new round of asset restructuring have been noted, with company management indicating plans to expand market share and seek external growth opportunities [7].

9月7日晚，向日葵（SZ300111，股价4.96元，市值63.85亿元）公告，公司正在筹划以发行股份及 （或）支付现金的方式收购漳州兮璞材料科技有限公司（以下简称兮璞材料）的控股权及浙江贝得药业 有限公司（以下简称贝得药业）40%股权，同时拟募集配套资金。本次交易尚处于筹划阶段，截至本公 告披露日，兮璞材料及贝得药业的估值尚未最终确定。经初步测算，本次交易预计构成《上市公司重大 资产重组管理办法》规定的重大资产重组。本次交易不会导致公司实际控制人发生变更，不构成重组上 市。 公开资料显示，兮璞材料是一家半导体市场电子材料供应商，致力于开发半导体市场的先进材料。如果 收购成功，向日葵将由一家化学制药企业跨界进入半导体领域，开辟一条新的赛道。 《每日经济新闻》记者注意到，9月5日，向日葵股价午后盘中涨幅一度超过14%，截至当日收盘涨幅仍 达11.96%，总市值攀升至63.85亿元。 本次交易预计构成重大资产重组 从交易框架来看，向日葵此次重大资产重组涉及两家标的公司，且已与核心交易对方签署意向协议，交 易细节与合规属性已初步明确。 对于贝得药业，公告显示其目前已是向日葵的控股子公司。天眼查信息显示，向日葵持有贝 ...